이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Nath Bio-Genes (India) 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Satish Kagliwal

최고 경영자

₹6.6m

총 보상

CEO 급여 비율	100.0%
CEO 임기	25.1yrs
CEO 소유권	n/a
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	3.8yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Satish Kagliwal 의 보수는 Nath Bio-Genes (India) 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	₹398m
Mar 31 2024	₹7m	₹7m	₹396m
Dec 31 2023	n/a	n/a	₹374m
Sep 30 2023	n/a	n/a	₹379m
Jun 30 2023	n/a	n/a	₹374m
Mar 31 2023	₹5m	₹5m	₹350m
Dec 31 2022	n/a	n/a	-₹827m
Sep 30 2022	n/a	n/a	-₹813m
Jun 30 2022	n/a	n/a	-₹815m
Mar 31 2022	₹5m	₹5m	-₹674m
Dec 31 2021	n/a	n/a	₹561m
Sep 30 2021	n/a	n/a	₹575m
Jun 30 2021	n/a	n/a	₹593m
Mar 31 2021	₹5m	₹5m	₹557m
Dec 31 2020	n/a	n/a	₹562m
Sep 30 2020	n/a	n/a	₹558m
Jun 30 2020	n/a	n/a	₹565m
Mar 31 2020	₹5m	₹5m	₹505m
Dec 31 2019	n/a	n/a	₹482m
Sep 30 2019	n/a	n/a	₹478m
Jun 30 2019	n/a	n/a	₹477m
Mar 31 2019	₹5m	₹5m	₹384m
Dec 31 2018	n/a	n/a	₹349m
Sep 30 2018	n/a	n/a	₹353m
Jun 30 2018	n/a	n/a	₹353m
Mar 31 2018	₹3m	₹3m	₹294m

보상 대 시장: Satish 의 총 보상 ($USD 78.66K )은 Indian 시장( $USD 37.60K ).

보상과 수익: Satish 의 보상은 지난 1년 동안 20% 이상 증가했습니다.

CEO

Satish Kagliwal (67 yo)

25.1yrs

테뉴어

₹6,600,000

보상

Mr. Satish Kagliwal serves as the Chairman of the Board at Agri-tech (India) Limited and has been its Executive Director since August 30, 1999 & serves as it's Managing Director of Agri-tech (India) Limite...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Satish Kagliwal	MD & Executive Director	25.1yrs	₹6.60m	데이터 없음
Jeevanlata Kagliwal	Executive Director	5.3yrs	₹20.00k	0.0015% ₹ 63.2k
Akash Kagliwal	Non-Executive Director	1.4yrs	₹15.00k	데이터 없음
Hitesh Purohit	Independent Non-Executive Director	2.5yrs	₹20.00k	데이터 없음
Ashu Jain	Independent Non-Executive Director	3.9yrs	₹20.00k	데이터 없음
Vadla Nagabhushanam	Independent Non-Executive Director	3.8yrs	₹23.00k	데이터 없음
Madhukar Deshpande	Independent Non-Executive Director	3.6yrs	₹23.00k	데이터 없음

3.8yrs

평균 재임 기간

64yo

평균 연령

경험이 풍부한 이사회: 537291 의 이사회는 경험(평균 재직 기간 3.8 년)으로 간주됩니다.

Nath Bio-Genes (India) 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Nath Bio-Genes (India) Limited, Annual General Meeting, Aug 17, 2024

Nath Bio-Genes (India) Limited Announces Resignation of Shrirang Shrikishan Agrawal as Independent Director

Nath Bio-Genes (India) Limited Appoints Madhukar Deshpande as Independent Director (Additional)

Nath Bio-Genes (India) Limited Announces Management Changes

Nath Bio-Genes (India) Limited Announces Demise of Omprakash Ramnarayan Sharma as an Independent Director on Board and Committees

Nath Bio-Genes (India) Limited Announces Board Changes

Recent updates

Nath Bio-Genes (India) Limited Declares Final Dividend for Financial Year Ended March 31, 2024

Upcoming dividend of ₹2.00 per share

Nath Bio-Genes (India) Limited to Report Q1, 2025 Results on Aug 07, 2024

Full year 2024 earnings released: EPS: ₹20.85 (vs ₹18.42 in FY 2023)

Investor sentiment improves as stock rises 20%

Investor sentiment improves as stock rises 19%

Full year 2024 earnings released: EPS: ₹21.34 (vs ₹18.42 in FY 2023)

Nath Bio-Genes (India) Limited, Annual General Meeting, Aug 17, 2024

Nath Bio-Genes (India) Limited Recommends Dividend for Financial Year 2023-24

Third quarter 2024 earnings released: EPS: ₹2.02 (vs ₹0.71 in 3Q 2023)

Nath Bio-Genes (India) Limited to Report Q3, 2024 Results on Jan 18, 2024

Second quarter 2024 earnings released: EPS: ₹0.86 (vs ₹0.77 in 2Q 2023)

Nath Bio-Genes (India) Limited to Report Q2, 2024 Results on Oct 16, 2023

Nath Bio-Genes (India) Limited to Report Q1, 2024 Results on Aug 10, 2023

Nath Bio-Genes (India) Limited Approves Final Dividend for Financial Year Ended 31St March 2023

Investor sentiment improves as stock rises 18%

Upcoming dividend of ₹2.00 per share at 1.1% yield

Full year 2023 earnings released: EPS: ₹18.42 (vs ₹35.46 loss in FY 2022)

Investor sentiment improves as stock rises 15%

Full year 2023 earnings released: EPS: ₹18.42 (vs ₹35.43 loss in FY 2022)

Third quarter 2023 earnings released: EPS: ₹0.71 (vs ₹1.48 in 3Q 2022)

Nath Bio-Genes (India) Limited to Report Q3, 2023 Results on Feb 14, 2023

Now 20% undervalued after recent price drop

Second quarter 2023 earnings released: EPS: ₹0.77 (vs ₹0.65 in 2Q 2022)

Nath Bio-Genes (India) Limited to Report Q2, 2023 Results on Oct 20, 2022

Nath Bio-Genes (India) Limited Announces Resignation of Shrirang Shrikishan Agrawal as Independent Director

First quarter 2023 earnings released: EPS: ₹16.18 (vs ₹23.63 in 1Q 2022)

Nath Bio-Genes (India) Limited to Report Q1, 2023 Results on Aug 13, 2022

Nath Bio-Genes (India) Limited Declares Dividend for the Financial Year Ended March 31, 2022

Upcoming dividend of ₹2.00 per share

Full year 2022 earnings released: ₹35.43 loss per share (vs ₹29.29 profit in FY 2021)

Nath Bio-Genes (India) Limited Recommends Dividend for the Financial Year 2021-2022

Nath Bio-Genes (India) Limited to Report Q4, 2022 Results on May 30, 2022

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Nath Bio-Genes (India) Limited to Report Q3, 2022 Results on Feb 11, 2022

Second quarter 2022 earnings released: EPS ₹0.65 (vs ₹1.59 in 2Q 2021)

Full year 2021 earnings released: EPS ₹29.29 (vs ₹26.57 in FY 2020)

Full year 2021 earnings released: EPS ₹29.29 (vs ₹26.57 in FY 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

New 90-day high: ₹306

Nath Bio-Genes (India) Limited Appoints Madhukar Deshpande as Independent Director (Additional)

Third quarter 2021 earnings released: EPS ₹2.23 (vs ₹2.05 in 3Q 2020)

Nath Bio-Genes (India) Limited to Report Q3, 2021 Results on Feb 10, 2021

Nath Bio-Genes (India) Limited Announces Management Changes

Nath Bio-Genes (India) Limited Announces Demise of Omprakash Ramnarayan Sharma as an Independent Director on Board and Committees

Second quarter 2021 earnings released: EPS ₹1.59

Nath Bio-Genes (India) Limited Announces Board Changes

Nath Bio-Genes (India) Limited Appoints Ashu Jain as an Additional Director (Independent)

New 90-day low: ₹252

New 90-day low - ₹297

First quarter earnings released

New 90-day high - ₹379

Nath Bio-Genes (India) Limited to Report Q1, 2021 Results on Aug 07, 2020

Nath Bio-Genes (India) Limited (BSE:537291) acquired entire seed business and related activity of Global Transgenes Limited for approximately INR 120 million.

New 90-day high - ₹357

CEO 보상 분석

CEO

테뉴어

보상

이사회 구성원

평균 재임 기간

평균 연령